A European regulatory panel recently issued a positive opinion recommending marketing authorization for guselkumab for the treatment of moderate to severe plaque psoriasis in the European Union.
Janssen-Cilag International, a Johnson & Johnson company, recently received the positive opinion by the Committee for Medicinal Products for Human Use for guselkumab for treating the painful and disabling disease, which has no cure and is the most common of all immune system skin disorders, a Johnson &Johnson release said.
The testing of the drug found that there were favorable outcomes in terms of skin condition in the first 16 weeks with few to no adverse effects, the release said.
The European Commission is expected to issue a final decision on guselkumab, which would be marketed under the trade name Tremfya, later this year, the release said.
